Delcath Systems CEO fired, board considers options after FDA rejection
This article was originally published in Clinica
Executive Summary
Delcath Systems booted its CEO and the company’s board is reviewing options after the US FDA handed the drug and device maker a widely expected rejection for a cancer therapy.